Luxembourg-based Droia, a specialist investor focused on oncology therapeutics, has announced the completion of its second fund, Droia II, with 150 million euros ($170.4 million) in commitment.
Droia II will inject worldwide in early stage drug development companies and in the establishment of new companies that apply novel science and innovative approaches to bring the most promising cancer therapies to patients.
The second fund was secured to further develop Droia’s proven investment model, which leverages Droia’s in-house oncology expert team to guide and assist portfolio companies in a rapidly evolving landscape.
Droia II was backed by the investors of Droia I, who were joined by a series of new institutional and private backers.